JW Therapeutics has appointed Dr. Shaun Paul Cordoba as CSO and Raymond J. Hage, Jr. as SVP of Corporate Development. Dr. Cordoba will oversee early-stage research and development, as well as provide scientific leadership and strategic guidance to construct a viable cell immunotherapy pipeline, in his newly appointed CSO role. As SVP of Corporate Development, Mr. Hage will oversee corporate strategy development and commercial alliances in order to strengthen and expand the pipeline in the near and long term.

Dr. Cordoba is a well-known scientist who has been at the forefront of new innovations in cell immunotherapy technology. He has rankedranked third in the world for patent holdings in Chimeric Antigen Receptor (CAR) technology, with over 270 patent filings related to boosting CAR activity, protecting CAR-T cells from immunosuppression, and improving CAR safety. Dr. Cordoba held positions at Autolus Therapeutics as the Executive Director of Synthetic Biology and Cell Signaling, where he oversaw a team of scientists focusing on the development of Chimeric Antigen Receptors (CARs) for both hematological and solid tumors. He has a Ph.D. in Immunology from the University of Sydney and has worked as a postdoctoral researcher at the University of Oxford, Imperial College London, and University College London.

Mr. Hage has strong business acumen and extensive experience in the biotech and pharmaceutical industries. He is the founder of Hapten Sciences and an advisor to biotech and vaccine companies and venture funds. He was previously the Senior Vice President of Commercial Operations and Chief Operating Officer of Novavax, Inc., a publicly traded vaccine business. Mr. Hage has held a range of positions with Cephalon (Teva) and Eli Lilly & Co. and has led many activities including product development, corporate strategy, commercial operations, and corporate development. Mr. Hage earned his MBA from The Ohio State University’s Fisher College of Business.

James Li, Co-founder, Chairman, CEO, JW Therapeutics, said, “The additions of of Dr. Cordoba and Mr. Hage to our senior leadership team bring a wealth of knowledge, experience, expertise that will be vital to JW Therapeutics during the next stage of growth. We will continue to optimize the technology platform to expand our product pipelines, to deliver breakthrough cell immunotherapy products to patients.”